UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.43 USD
-0.01 (-0.69%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
UBX 1.43 -0.01(-0.69%)
Will UBX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UBX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UBX
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
UBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Unity (UNX) Down on Disappointing Results From Wet AMD Study
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
Other News for UBX
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
Unity Biotechnology initiated with bullish view at Rodman & Renshaw
UNITY Biotechnology to Participate in Upcoming Investor Conferences
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Foselutoclax Trial Results and Strong Financial Position
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates